Neonatal seizures—diagnostic options and treatment recommendations

Seizures in neonates should prompt rapid evaluation to verify the diagnosis, determine etiology, and initiate appropriate treatment. Neonatal seizure diagnosis requires EEG confirmation and clinical observation alone is insufficient. Although most neonatal seizures are related to acute brain injury, some neonates present early-onset structural or metabolic/genetic epilepsy. Video-EEG monitoring, the gold standard for neonatal seizure detection and quantification, is resource-intensive and often unavailable, with amplitude-integrated EEG offering a reasonable alternative in guiding treatment. Whereas new-generation antiseizure medication (ASM), such as levetiracetam, appear promising, particularly in terms of tolerability, older-generation ASM, such as phenobarbital and phenytoin, are yet to be replaced. Acute treatment should aim at stopping both electroclinical and electrographic-only seizures. In neonates with acute provoked seizures, ASM should be discontinued without tapering after 72 h of seizure freedom and before hospital discharge.

Neonatal seizures are often the first and most common neurological sign in neonates. Seizures occur more frequently in the first week of life than at any other time, with a reported incidence of 1-4 in 1000 neonates, and higher rates reported in preterm neonates and in those with lower gestational age and birth weight [13]. Seizures may suggest the presence of a potentially treatable disorder and should therefore prompt a timely workup and treatment initiation [14,18]. Neonatal seizures, notably recurrent or prolonged, can cause further brain injury, thus increasing the risk for poor neurological outcomes, including cognitive and motor impairment and post-neonatal epilepsy [14,16]. Recent advances in diagnostics, including full EEG, amplitude-integrated EEG (aEEG), magnetic resonance imaging, metabolic and genetic test-ing, have drastically improved seizure detection and facilitated etiologic classification, paving the way for targeted treatment and potentially optimal outcomes. However, despite the integration of ground-breaking preclinical research and the implementation of cutting-edge technology in clinical research, treating neonatal seizures still poses a challenge for clinicians.

Etiology
Neonatal seizures are unique since most relate to acute brain injuries such as hypoxic-ischemic encephalopathy (HIE), structural brain injury-including ischemic and hemorrhagic stroke-and metabolic derangements, usually of glucose and electrolytes-and central nervous system or systemic infections. Intraventricular hemorrhage in premature neonates and HIE in term neonates are the predominant etiology of acute provoked seizures. Onlỹ 15% of neonatal seizures are related to neonatal-onset epilepsy [14,18] that may arise from structural brain abnormalities (structural epilepsies), such as malformations of cortical development, or genetic conditions (genetic epilepsies), such as ion channel and vitamin-dependent disorders [28]. Recurrent seizures in otherwise healthy neonates with overall negative findings may correspond to self-limited neonatal epilepsy with an excellent prognosis, whereas recurrent seizures in severely affected neonates with neurological deficit may indicate an early infantile developmental and epileptic encephalopathy with particularly poor prognosis.

Diagnostic options
Electroencephalography Although neonatal seizures have been commonly diagnosed based on clinical semiology alone, recent studies have Hier steht eine Anzeige.

K
shown that EEG confirmation is essential to avoid misdiagnosis and guide treatment. Not all clinically suspicious events in preterm or term neonates correspond to seizures and most neonatal seizures are electrographic-only. The high rate of uncoupling, meaning that electroclinical seizures become electrographic-only following the administration of anti-seizure medication (ASM)-notably phenobarbital and phenytoin-in affected neonates, adds to this challenge [3,20,27].
The American Clinical Neurophysiology Society (ACNS) has defined electrographic neonatal seizures as sudden, abnormal EEG events defined by a repetitive and evolving pattern with a voltage of >2 μV and a duration of > 10 s. "Evolving" is defined as an unequivocal evolution in frequency, voltage, morphology, or location, i.e., increasing amplitude and decreasing frequency of discharges over time [26]. When these EEG changes are related to simultaneously coupled definite clinical signs, the seizure is defined as electro-clinical; otherwise, the seizure is defined as electrographiconly. However, the definition of neonatal seizures has been reconsidered, and their duration is currently not strictly defined but has to be sufficient to (1) demonstrate an evolution in frequency and morphology of the discharges and (2) allow for the recognition of onset, evolution, and resolution of an abnormal discharge [15], with the exception of myoclonic seizures and spasms. Interestingly, EEG seizure patterns in neonates often show a focal onset and evolution, although not necessarily reflecting a focal pathology [18]. Although no consensus definition of neonatal status epilepticus is yet available [15], this may be diagnosed when the summed duration of seizures comprises ≥ 50% of an arbitrarily defined 1-h epoch.
Continuous video EEG (v-EEG) is the gold standard for reliable neonatal seizure detection, prompt treatment initiation, and monitoring. For neonates at high risk of seizures, the ACNS recommends v-EEG for 24 h [23]. In a prospective cohort study of neonates with clinically suspicious events or electrographic seizures who underwent v-EEG, the median time from the beginning of the recording to An integrative approach to neuromonitoring in high-risk neonates with v-EEG and, ideally, a multicamera setup instead of the standard single-camera can significantly increase diagnostic accuracy. However, v-EEG is expensive, time-consuming, and moderately invasive, while its rapid installation and realtime interpretation are prohibitive since it would require the 24/7 availability of skilled technical and medical personnel [16,18]. To address this issue, a flexible frame of recommendations for neonatal units, encompassing different levels of complexity, local resources, and patient features, has been recently proposed [5]. Novel automated seizure detection algorithms and seizure-burden analyses developed for use in clinical settings may enhance seizure detection and provide decision support. Although no automated algorithm is reliable enough to replace experienced EEG specialists, future clinical trials will undoubtedly profit from these technological developments.

Amplitude-integrated EEG
Amplitude-integrated EEG (aEEG), with its time-compressed, one-or two-channel EEG trend presented on a semi-logarithmic scale, is increasingly applied as an adjuvant tool for continuous monitoring of affected neonates. Particularly in HIE, aEEG is an adjunctive criterion for the introduction of therapeutic hypothermia. Reducing electrode placement and interpretation time compared to conventional EEG, aEEG enables the assessment of the background activity and facilitates the earlier recognition of state changes. However, aEEG is considerably less accurate than conventional EEG for seizure detection, especially for seizures (1) arising outside the centro-temporal regions, (2) featuring a short duration, and (3) consisting of low-voltage slow discharges. However, seizures are generally more common in the central regions, and these seizure patterns can be correctly identified in 70-80% of cases since they are sampled by aEEG [24]. Although seizure detection by aEEG has been shown to miss 20% of neonatal seizures compared to full EEG, even when used by aEEG experts [25], aEEG-based seizure detection is still more reliable than clinical diagnosis alone [8].
Seizures can be detected in the aEEG as "saw-tooth-like" augmentations of the baseline amplitude but should be confirmed by examining the simultaneous EEG trace to rule out artifacts that pollute these unattended EEG recordings without simultaneous video.

Semiology
Seizure semiology can reveal specific etiologies (. Table 1). Myoclonic seizures should raise suspicions of a metabolic disorder such as non-ketotic hyperglycinemia, propionic acidemia, and vitamin B6dependent epilepsy. Focal motor clonic seizures are more frequently acute provoked, corresponding to a focal cortical lesion such as stroke, intracranial hemorrhage, and, more rarely, cortical dysplasia [19]. Motor tonic seizures often arise in genetically determined developmental epileptic encephalopathy (KCNQ2, CDKL5, STXBP1-related epilepsy, etc.) if a cortical malformation or an acute provoked etiology is unlikely based on clinical history. Sequences of a tonic followed by a myoclonic or clonic phase (sequential seizures) are a hallmark of KCNQ2-related epilepsy, the most common neonatalonset genetic epilepsy. Epileptic spasms in neonates are rare, primarily found in metabolic disorders, such as vitamin B6dependent epilepsy but also in cortical malformations or early-onset epileptic encephalopathy.

Classification
The Task

Symptomatic treatment
Starting anti-seizure medication Particularly in HIE, both preclinical and clinical studies have provided evidence that prolonged or recurrent seizures themselves may augment injury to the developing brain beyond that of the underlying etiology [16]. For electrographic seizures, the most common seizure type in neonates, a recent study showed that those treated within 1 h of seizure onset had a significantly lower seizure burden and fewer seizures over the subsequent 24 h. This effect was absent if ASM was started > 1 h from seizure onset, suggesting that the impact of ASM on seizure burden is timecritical, with an optimal efficacy within 1 h of seizure onset. Despite this recent evidence, the optimal timepoint for treatment initiation in neonatal seizures remains ill-defined, whereas a cumulative electrographic seizure burden of > 30 s/h has been proposed as the entry criterion for randomization in therapeutic trials for neonatal seizures.

Medication selection
The optimal ASM management of neonatal seizures is still under debate. In a 2004 Cochrane review [2], the authors concluded that "there is little evidence from randomized controlled trials to support the use of any of the anticonvulsants currently used in the neonatal period." Although neonatal seizure management pathways differ between institutions and settings, the most commonly used ASMs are phenobarbital (PB), phenytoin (PHT), and levetiracetam (LEV), with alternatives including lacosamide (LCM), and escalation to continuous midazolam (MDZ) infusion [11]. However, overall response rates to ASM are low, whereas the selflimited nature of acute provoked seizures and the potential neurotoxicity of ASM to the immature brain dictate caution. Standardized treatment protocols assessing ASM response in neonatal seizures may be crucial for improving outcomes and reducing adverse effects, morbidity, and mortality. Reassessing intravenous ASM efficacy 60 min from initiation has been linked to lower status epilepticus rates, lower PB concentrations, and shorter hospital stays. The oldest and most popular first-line ASM, PB displays efficacy in only half of the cases and produces the phenomenon of electroclinical uncoupling in treated neonates. Moreover, PB has been associated with widespread neuronal apoptosis [1] and impaired synaptic maturation [7] in the animal model. It should be noted that these studies have been performed on heathy rodents and their results have neither been confirmed in humans nor has the benefit-risk ratio been evaluated in immature rodents with seizures. The main adverse effects of PB, including hypotension, respiratory suppression, and sedation, are particularly relevant for neonates with severe encephalopathy. Third-generation ASMs with a good efficacy and safety profile, particularly LEV, have emerged as novel treatment options for neonatal seizures [17]. One of the key arguments for LEV use in neonatal seizures is the more favorable pharmacokinetics, characterized by a linear clearance, few drug interactions, and a broad therapeutic index. By contrast, PB is linked to auto-inducible clearance with use and numerous drug interactions. However, PB was considerably more effective than LEV for treating neonatal seizures in a recent randomized controlled study, although higher rates of adverse effects were seen with PB [22].
Among second-line ASM, it should be noted that lidocaine reached a response rate of 68% in full-term neonates, higher than MDZ. Concerns regarding lidocaine toxicity, mainly of cardiac arrhythmias, have been eased following the introduction of new reduced-dose regimens. Nevertheless, given these potential cardiac side effects, lidocaine should not be combined with other cardiotoxic agents, e.g., phenytoin/fosphenytoin (PHT/FPHT). Little is known about the use of newer ASM, such as brivaracetam, in the neonatal period, while other, older ASMs have limited use in the acute phase because of the unavailability of an intravenous formulation. No specific ASM is indicated for preterm neonates, despite the vast differences in pharmacokinetics and brain maturation.
Finally, therapeutic hypothermia in HIE may alter the metabolism of ASM, particularly in neonates with multiorgan dysfunction. Hypothermia prolongs clearance of PHT with increased risk of bradycardia and of lidocaine with increased risk of cardiotoxicity. By contrast, the rewarming phase of hypothermia may accelerate ASM metabolism.

Etiologic treatment
The choice of treatment should be guided by the etiology of neonatal seizures since, in some cases, specific and efficacious treatment choices are available for affected neonates [14,18]. Inborn errors of metabolism, diagnosed based on clinical presentation as well as biochemical investigations and verified by genetics, represent a significant challenge that needs to be rapidly addressed to avoid metabolic decompensation and facilitate prognostic counseling. Since early diagnosis enables precision medicine, i.e., etiologic treatment in selected metabolic disorders and specific ASM in selected neonatal-onset genetic epilepsies [12,21], a diagnostic algorithm designed to detect these disease entities is required in all neonatal units. This algorithm should include a standardized and well-documented vitamin B6 trial to identify defects in the ALDH7A1, PNPO, PLPBP gene or cases of severe congenital hypophosphatasia [18]. Finally, some early-onset genetic epilepsies may respond to sodium channel blockers such as carbamazepine, especially loss-of-function-KCNQ2 or gainof-function SCN2A/SCN8A. Clinical data regarding the use of quinidine in gain-offunction KCNT1 are, however, inconclusive [6].

Treatment duration
Since neonatal seizures are acute provoked in their majority, it has been suggested to wean medication to a single ASM before discharge or even withdraw ASM altogether when (1) only single or rare seizures have occurred, (2) the neonate has been seizure-free for at least 48-72 h, and (3) the risk of recurrence is not considered particularly high. Discontinuation of ASM prior to hospital discharge has not been related to a higher risk of post-neonatal epilepsy or less favorable neurodevelopmental outcomes at the 2-year follow-up. Therefore, while the World Health Organization recommends withdrawing ASM after 72 h of seizure freedom in those with normal EEG and neurological examination [29], others suggest expanding this recommendation to neonates with abnormal EEG and neurological examination [10]. However, if seizures are uncontrolled or neonatalonset epilepsy has been diagnosed [14], ASM should be maintained and neonates should be referred to specialized neuropediatric clinics for further management.

Schlüsselwörter
Neugeborenenanfälle · Termingeborene · Frühgeborene · EEG · Behandlung · Anfallsunterdrückende Medikation since renal, cardiovascular, and hepatic dysfunction are common. 4 In neonates with acute provoked seizures, ASM should be discontinued without tapering after 72 h of seizure freedom and before hospital discharge. Neonates with neonatal-onset epilepsy should be maintained on ASM and followed up closely in specialized neuropediatric clinics. 4 While diagnosing and treating neonatal seizures remains challenging, the development of novel, disease-modifying, or anti-epileptogenic therapies and new neuroprotective agents may ultimately improve neonatal seizure outcomes.